Iovance Biotherapeutics, Inc. is a leading biotech company in tumor-infiltrating lymphocyte (TIL) cell therapies, having recently transitioned to a commercial stage with its flagship product, Amtagvi (lifileucel), being approved for advanced melanoma. The company aims to expand its pipeline across other solid tumors and broaden its market reach, leveraging its proprietary TIL platform to pioneer new cancer treatments.